Drugs / GNS-212-E2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06317350 | Mar → Oct 2024 | — | Gunkang Pharmaceuticals, Inc | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GNS-212-E2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06317350 ↗ |